Cardinal Health, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jason Hollar
- Full Time Employees
- 57,700
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 7000 Cardinal Place Dublin OH United States of America 43017
- IPO Date
- Aug 4, 1983
- CIK
- 0000721371
- Website
- cardinalhealth.com
- Similar Companies
- Business
- Cardinal Health, Inc. (NYSE: CAH) provides integrated healthcare services and products, distributing pharmaceuticals and medical supplies to hospitals, pharmacies, and healthcare providers worldwide. The company manufactures branded and private-label medical, surgical, and laboratory products, including masks, gloves, gowns, and exam apparel under brands such as Aspen Surgical, Cardinal Health, and Trudell; offers nuclear pharmacy services, patient safety solutions, and pharmacy management software; and operates through three main segments: Pharmaceutical, Medical, and Home Health & Hospice. Its product portfolio encompasses over 20,000 national brand pharmaceuticals, over 2,000 generic drugs, and a broad range of medical-surgical supplies like needles, syringes, IV sets, and wound care items; services include third-party logistics, specialty pharmaceutical distribution, and proprietary navigation technology for at-home care. Cardinal Health serves independent retail pharmacies, chains, hospitals, ambulatory surgery centers, clinical laboratories, and physician offices primarily in the United States, Canada, and Puerto Rico, with headquarters in Dublin, Ohio, where it was founded in 1971. In recent developments, Cardinal Health completed the acquisition of Integrated Pharmacy Solutions in October 2024, expanding its 503A sterile compounding capabilities to support hospital pharmacies nationwide; launched a new Advanced Call Center in July 2024 to enhance customer service for its Medical segment; and announced a strategic distribution agreement with the Novo Nordisk Patient Assistance Program (PAP) in November 2024 to broaden access to essential medications. The company also secured a five-year Pharmaceutical Supply Agreement with the U.S. Department of Veterans Affairs in September 2024 valued at approximately $9.3 billion, reinforcing its position as a key government supplier; introduced the Cordless Navigation System for orthopedic procedures in 2024; and completed the divestiture of its Health Care Compliance business to RLDatix in December 2024. These moves reflect ongoing efforts to optimize operations, grow in high-margin areas like sterile compounding and navigation technology, and strengthen partnerships amid supply chain challenges.
Wall Street Analysts See Cardinal (CAH) as a Buy: Should You Invest?
Should You Retain CAH Stock After Removal From Several Russell Indices?
Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
Cardinal Health (CAH) Declines More Than Market: Some Information for Investors
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Cardinal Health: Why This Essential Healthcare Distributor Deserves A Buy Rating
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Why the Market Dipped But Cardinal Health (CAH) Gained Today
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
Cardinal Health (CAH) Ascends While Market Falls: Some Facts to Note
Here's Why Cardinal Health (CAH) is a Strong Growth Stock
CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026?
Cardinal Health (CAH) Stock Declines While Market Improves: Some Information for Investors
Is It Worth Investing in Cardinal (CAH) Based on Wall Street's Bullish Views?
The Healthcare M&A Wave
Here's Why Cardinal Health (CAH) is a Strong Value Stock
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Is Cardinal Health (CAH) Stock Undervalued Right Now?